Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial
© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.com..
BACKGROUND: We investigated the outcomes of postmenopausal women with hormone receptor-positive, early breast cancer with special histotypes (mucinous, tubular, or cribriform) enrolled in the monotherapy cohort of the BIG 1-98 trial.
PATIENTS AND METHODS: The intention-to-treat BIG 1-98 monotherapy cohort (5 years of therapy with tamoxifen or letrozole) included 4922 women, of whom 4091 had central pathology review. Histotype groups were defined as: mucinous (N = 100), tubular/cribriform (N = 83), ductal (N = 3257), and other (N = 651). Of 183 women with either mucinous or tubular/cribriform tumors, 96 were randomly assigned to letrozole and 87 to tamoxifen. Outcomes assessed were disease-free survival (DFS), overall survival (OS), breast cancer-free interval (BCFI), and distant recurrence-free interval (DRFI). Median follow-up in the analytic cohort was 8.1 years.
RESULTS: Women with tubular/cribriform breast cancer had the best outcomes for all end points compared with the other three histotypes, and had less breast cancer recurrence (97.5% 5-year BCFI) than those with mucinous (93.5%), ductal (88.9%), or other (89.9%) histotypes. Patients with mucinous or tubular/cribriform carcinoma had better DRFI (5-year rates 97.8% and 98.8%, respectively) than those with ductal (90.9%) or other (92.1%) carcinomas. Within the subgroup of women with special histotypes, we observed a nonsignificant increase in the hazard of breast cancer recurrence with letrozole [hazard (letrozole versus tamoxifen): 3.31, 95% confidence interval 0.94-11.7; P = 0.06].
CONCLUSIONS: Women with mucinous or tubular/cribriform breast cancer have better outcomes than those with other histotypes, although the observation is based on a limited number of events. In postmenopausal women with these histotypes, the magnitude of the letrozole advantage compared with tamoxifen may not be as large in patients with mucinous or tubular/cribriform disease.
CLINICALTRIALSGOV: NCT00004205.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Annals of oncology : official journal of the European Society for Medical Oncology - 26(2015), 12 vom: 13. Dez., Seite 2442-9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Munzone, E [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 12.09.2016 Date Revised 09.03.2022 published: Print-Electronic ClinicalTrials.gov: NCT00004205 Citation Status MEDLINE |
|---|
| doi: |
10.1093/annonc/mdv391 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM252917715 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM252917715 | ||
| 003 | DE-627 | ||
| 005 | 20231224165128.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/annonc/mdv391 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0843.xml |
| 035 | |a (DE-627)NLM252917715 | ||
| 035 | |a (NLM)26387144 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Munzone, E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.09.2016 | ||
| 500 | |a Date Revised 09.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT00004205 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: We investigated the outcomes of postmenopausal women with hormone receptor-positive, early breast cancer with special histotypes (mucinous, tubular, or cribriform) enrolled in the monotherapy cohort of the BIG 1-98 trial | ||
| 520 | |a PATIENTS AND METHODS: The intention-to-treat BIG 1-98 monotherapy cohort (5 years of therapy with tamoxifen or letrozole) included 4922 women, of whom 4091 had central pathology review. Histotype groups were defined as: mucinous (N = 100), tubular/cribriform (N = 83), ductal (N = 3257), and other (N = 651). Of 183 women with either mucinous or tubular/cribriform tumors, 96 were randomly assigned to letrozole and 87 to tamoxifen. Outcomes assessed were disease-free survival (DFS), overall survival (OS), breast cancer-free interval (BCFI), and distant recurrence-free interval (DRFI). Median follow-up in the analytic cohort was 8.1 years | ||
| 520 | |a RESULTS: Women with tubular/cribriform breast cancer had the best outcomes for all end points compared with the other three histotypes, and had less breast cancer recurrence (97.5% 5-year BCFI) than those with mucinous (93.5%), ductal (88.9%), or other (89.9%) histotypes. Patients with mucinous or tubular/cribriform carcinoma had better DRFI (5-year rates 97.8% and 98.8%, respectively) than those with ductal (90.9%) or other (92.1%) carcinomas. Within the subgroup of women with special histotypes, we observed a nonsignificant increase in the hazard of breast cancer recurrence with letrozole [hazard (letrozole versus tamoxifen): 3.31, 95% confidence interval 0.94-11.7; P = 0.06] | ||
| 520 | |a CONCLUSIONS: Women with mucinous or tubular/cribriform breast cancer have better outcomes than those with other histotypes, although the observation is based on a limited number of events. In postmenopausal women with these histotypes, the magnitude of the letrozole advantage compared with tamoxifen may not be as large in patients with mucinous or tubular/cribriform disease | ||
| 520 | |a CLINICALTRIALSGOV: NCT00004205 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a breast cancer | |
| 650 | 4 | |a cribriform | |
| 650 | 4 | |a letrozole | |
| 650 | 4 | |a mucinous | |
| 650 | 4 | |a tamoxifen | |
| 650 | 4 | |a tubular | |
| 650 | 7 | |a Antineoplastic Agents, Hormonal |2 NLM | |
| 650 | 7 | |a Nitriles |2 NLM | |
| 650 | 7 | |a Triazoles |2 NLM | |
| 650 | 7 | |a Tamoxifen |2 NLM | |
| 650 | 7 | |a 094ZI81Y45 |2 NLM | |
| 650 | 7 | |a Letrozole |2 NLM | |
| 650 | 7 | |a 7LKK855W8I |2 NLM | |
| 700 | 1 | |a Giobbie-Hurder, A |e verfasserin |4 aut | |
| 700 | 1 | |a Gusterson, B A |e verfasserin |4 aut | |
| 700 | 1 | |a Mallon, E |e verfasserin |4 aut | |
| 700 | 1 | |a Viale, G |e verfasserin |4 aut | |
| 700 | 1 | |a Thürlimann, B |e verfasserin |4 aut | |
| 700 | 1 | |a Ejlertsen, B |e verfasserin |4 aut | |
| 700 | 1 | |a MacGrogan, G |e verfasserin |4 aut | |
| 700 | 1 | |a Bibeau, F |e verfasserin |4 aut | |
| 700 | 1 | |a Lelkaitis, G |e verfasserin |4 aut | |
| 700 | 1 | |a Price, K N |e verfasserin |4 aut | |
| 700 | 1 | |a Gelber, R D |e verfasserin |4 aut | |
| 700 | 1 | |a Coates, A S |e verfasserin |4 aut | |
| 700 | 1 | |a Goldhirsch, A |e verfasserin |4 aut | |
| 700 | 1 | |a Colleoni, M |e verfasserin |4 aut | |
| 700 | 0 | |a International Breast Cancer Study Group and the BIG 1-98 Collaborative Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology : official journal of the European Society for Medical Oncology |d 1990 |g 26(2015), 12 vom: 13. Dez., Seite 2442-9 |w (DE-627)NLM012606308 |x 1569-8041 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2015 |g number:12 |g day:13 |g month:12 |g pages:2442-9 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/annonc/mdv391 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2015 |e 12 |b 13 |c 12 |h 2442-9 | ||